Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Glaucoma
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Glaucoma
    TopAbstracts in Glaucoma 11/16/2009 - (DGNews)
    External Trabeculotomy Offers Fewer Complications Than Trabeculectomy for Treating Steroid-Induced Glaucoma: Presented at AAO-PAAO - (DGDispatch)
    Future of Glaucoma Management: Presented at AAO-PAAO - (DGDispatch)
    Intravitreal Bevacizumab Provides Pain Relief, Improves Surgical Results in Patients With Neovascular Glaucoma: Presented at AAO-PAAO - (DGDispatch)
    Trabecular Microbypass Stent Safe, Effective for Refractory Open-Angle Glaucoma: Presented at AAO-PAAO - (DGDispatch)

    News archive

     Recent webcasts/CME - Glaucoma
    Adjunctive Medical Therapy: New Evidence and Treatment Strategies for Glaucoma
    Enhancing Adherence with Glaucoma Therapy: Practical Strategies for Superior Outcomes

    Webcasts/CME archive

     Recent cases - Glaucoma
      Intravitreal Bevacizumab in the Treatment of Neovascular Glaucoma Secondary to Central Retinal Vein Occlusion: A Case Report
      Topiramate-Associated Acute Glaucoma in a Migraine Patient Receiving Concomitant Citalopram Therapy: A Case-Report
      Central Retinal Artery Occlusion and Non-Arteritic Anterior Ischemic Optic Neuropathy Associated with an Overlap Syndrome: A Case Report
      Argon Laser Peripheral Iridoplasty for Plateau Iris Associated with Iridociliary Cysts: A Case Report
      Missed Case of Axenfeld-Rieger Syndrome: A Case Report

      Cases archive
        




      my personal edition > glaucoma > news
      divider

        E-Mail this DGDispatch to a colleague

      DGDispatch


      Ex-PRESS Implant Reduces Intraocular Pressure in Patients With Open-Angle Glaucoma: Presented at AAO

      By Deanna M Green, PhD

      ANAHEIM, CA -- November 20, 2003 -- Ocular implantation of the Ex-PRESS device in patients with open-angle glaucoma (OAG) significantly lowers intraocular pressure (IOP) and reduces the need for antiglaucoma medication, according to findings presented here November 17th at the American Academy of Ophthalmology's 2003 Annual Meeting.

      Trabeculectomy is the most common surgical treatment for glaucoma. However, this procedure is not an option for patients with scarring or trauma and is associated with a number of serious complications, including infection, choroidal detachment, and choroidal haemorrhaging.

      One alternative treatment for patients with OAG is the minimally invasive Ex-PRESS miniature glaucoma implant. The device was designed to reduce IOP by diverting excess aqueous humour from the anterior chamber to a subconjunctival bleb. The Ex-PRESS implant holds several advantages over traditional filtration surgery, including ease of implantation and decreased trauma to the ocular tissue.

      Carlo E Traverso, MD, at the University of Genoa, Italy, and colleagues evaluated the safety and efficacy of the Ex-PRESS miniature glaucoma implant (Optonol Ltd.) when implanted in combination with cataract extraction.

      The multicentre, open-label prospective study included 26 patients (mean age, 75) with OAG and impaired vision due to cataracts. Phacoemulsification cataract extraction was performed, followed by implantation of the Ex-PRESS device under the conjunctiva at the limbus. Patients were examined up to two years postoperatively.

      Overall, IOP was reduced by 39.4% 6 months after implantation and by 32.5% at 2 years. More specifically, the mean IOP dropped from 24.5 mmHg preoperatively to 15.3 mmHg at 1 year and 16.6 mmHg at 2 years.

      A target IOP of </=21 mmHg was achieved in 88.5% of patients at final follow up. Notably, this success rate was 69.2% when only patients who did not receive adjunct antiglaucoma medication were considered.

      The average number of antiglaucoma medications used by these patients was also significantly reduced -- from 2.7 preoperatively to less than 0.5 at 24 months (P < .001). At final follow-up, seven patients were still medicated, six of whom were taking only one medication.

      The most common complication was hyphema <2mm, which occurred one day after surgery in three patients and resolved within one week. Other complications included device rotation (2 patients), choroidal detachment due to rubbing (1), and erosion (1) at 2 years.

      Postoperative intervention was necessary in eight patients: five required needling with 5-fluorouracil, two required 5-fluorouracil injection, and one required needling without 5-fluorouracil.

      "The Ex-PRESS is a safe and effective implant for reducing IOP and antiglaucoma medications in OAG eyes in combination with cataract extraction," Dr. Traverso concluded. He also noted that "optimal positioning of the implant may further reduce the number of complications."


      [Study title: Long-Term Follow-Up of the Ex-PRESS Implant in Open-Angle Glaucoma Patients. Abstract PO206]



      E-Mail this DGDispatch to a colleague   To print, use this version






      All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send